Loading stock data…
Apnimed, Inc. (APMD)
$28.79+1.34 (+4.88%)
After Hours$29.00+0.21 (+0.73%)· Last close Sep 8
Apnimed, Inc.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $84.81M↑ | $3.13M |
| Gross Profit | $82.65M↑ | $1.81M |
| Operating Income | $68.04M↑ | -$27.11M |
| Net Income | $70.37M↑ | -$28.65M |
Peer Comparison
JNJUNHPFE
Fundamentals
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat ob...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.20B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
11.85
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
16.20%
Volume
Today's trading volume
380,636
Recent News
BofA makes bullish call on newly public biotech stock
Bank of America sees a differentiated opportunity in a breakthrough sleep apnea pill.
Moderna Stock Carries A Market Value Its Revenue Does Not Support
Moderna's commercial business has shrunk and is lossmaking, which puts the weight of its market value on a pipeline rather than on revenue.
Apnimed shares surge on bullish BofA initiation
Shares of Apnimed rose 8% Tuesday after BofA Securities initiated coverage of the company with a Buy rating and a $41 price target. The rating is based on a risk-adjusted discounted cash flow analysis of Oxnimbi (AD109), Apnimed's sole asset and an oral therapy for obstructive sleep apnea...
Moderna Stock Had A Readout Waiting In Plain Sight
Before the melanoma result, the visible signs were an enrolled trial, a partner paying half its cost, and a market that had stopped pricing an unusually large move.
Moderna's Melanoma Result Landed On A Market Positioned The Other Way
The trial met both endpoints in the readout, removing the inconclusive outcome management itself had flagged, and short sellers in the stock took a record single-session loss.